Hayek Kallen Investment Management’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.29M Sell
94,912
-1,227
-1% -$32.1K 0.69% 38
2026
Q1
$2.7M Buy
+96,139
New +$2.56M 0.88% 36
2025
Q4
Sell
-105,093
Closed -$2.68M 154
2025
Q3
$2.68M Sell
105,093
-1,392
-1% -$34.4K 0.85% 32
2025
Q2
$2.58M Sell
106,485
-85
-0.1% -$1.98K 0.88% 32
2025
Q1
$2.7M Buy
106,570
+3,588
+3% +$93.9K 0.99% 31
2024
Q4
$2.73M Sell
102,982
-3,598
-3% -$97.6K 0.99% 30
2024
Q3
$3.08M Sell
106,580
-334
-0.3% -$9.74K 1.09% 28
2024
Q2
$2.99M Sell
106,914
-506
-0.5% -$13.9K 1.12% 29
2024
Q1
$2.98M Buy
107,420
+3,873
+4% +$107K 1.14% 29
2023
Q4
$2.98M Buy
103,547
+1,355
+1% +$41K 1.24% 28
2023
Q3
$3.39M Buy
102,192
+665
+0.7% +$23.5K 1.52% 24
2023
Q2
$3.72M Buy
101,527
+2,813
+3% +$109K 1.58% 21
2023
Q1
$4.03M Sell
98,714
-2,298
-2% -$99.3K 1.82% 18
2022
Q4
$5.18M Sell
101,012
-2,360
-2% -$113K 2.39% 12
2022
Q3
$4.52M Sell
103,372
-8
-0% -$389 2.12% 12
2022
Q2
$5.42M Sell
103,380
-170
-0.2% -$8.66K 2.36% 11
2022
Q1
$5.36M Sell
103,550
-122
-0.1% -$6.33K 1.99% 15
2021
Q4
$6.12M Sell
103,672
-679
-0.7% -$33.6K 2.18% 12
2021
Q3
$4.49M Sell
104,351
-562
-0.5% -$24.9K 2.05% 16
2021
Q2
$4.11M Buy
104,913
+392
+0.4% +$15.2K 1.73% 21
2021
Q1
$3.79M Buy
104,521
+364
+0.3% +$12.9K 1.71% 22
2020
Q4
$3.83M Sell
104,157
-5,166
-5% -$189K 1.85% 20
2020
Q3
$3.81M Buy
109,323
+24
+0% +$841 2.13% 13
2020
Q2
$3.39M Buy
109,299
+2,792
+3% +$94.9K 1.92% 18
2020
Q1
$3.3M Buy
106,507
+229
+0.2% +$7.8K 2.21% 16
2019
Q4
$3.95M Buy
106,278
+2,525
+2% +$89.9K 2.28% 15
2019
Q3
$3.54M Buy
103,753
+1,243
+1% +$45.2K 2.21% 18
2019
Q2
$4.21M Buy
102,510
+325
+0.3% +$12.9K 2.67% 11
2019
Q1
$4.12M Buy
102,185
+840
+0.8% +$33.6K 2.67% 13
2018
Q4
$4.2M Sell
101,345
-447
-0.4% -$18.6K 3.01% 10
2018
Q3
$4.26M Sell
101,792
-492
-0.5% -$18.9K 2.73% 12
2018
Q2
$3.52M Sell
102,284
-1,883
-2% -$64.3K 2.43% 14
2018
Q1
$3.51M Sell
104,167
-2,481
-2% -$85.3K 2.43% 15
2017
Q4
$3.66M Sell
106,648
-2,112
-2% -$72K 2.4% 16
2017
Q3
$3.68M Sell
108,760
-288
-0.3% -$9.26K 2.52% 14
2017
Q2
$3.48M Buy
109,048
+6,993
+7% +$221K 2.35% 18
2017
Q1
$3.31M Buy
102,055
+5,348
+6% +$169K 2.3% 18
2016
Q4
$2.98M Buy
96,707
+2,145
+2% +$65.5K 2.17% 22
2016
Q3
$3.04M Buy
94,562
+3,360
+4% +$112K 2.17% 24
2016
Q2
$3.05M Buy
91,202
+1,537
+2% +$49.1K 2.19% 23
2016
Q1
$2.52M Buy
89,665
+3,822
+4% +$109K 1.87% 27
2015
Q4
$2.63M Sell
85,843
-387
-0.4% -$12.2K 2.01% 25
2015
Q3
$2.57M Sell
86,230
-1,622
-2% -$52K 2% 26
2015
Q2
$2.79M Buy
87,852
+7,386
+9% +$241K 2.09% 23
2015
Q1
$2.66M Buy
80,466
+2,425
+3% +$77.1K 1.96% 25
2014
Q4
$2.31M Buy
78,041
+3,741
+5% +$107K 1.7% 27
2014
Q3
$2.08M Buy
74,300
+18,899
+34% +$530K 1.59% 27
2014
Q2
$1.56M Buy
55,401
+10,148
+22% +$289K 1.18% 30
2014
Q1
$1.38M Buy
45,253
+3,500
+8% +$104K 1.1% 31
2013
Q4
$1.21M Buy
41,753
+1,442
+4% +$42K 0.94% 33
2013
Q3
$1.1M Buy
40,311
+3,125
+8% +$85K 0.91% 34
2013
Q2
$988K Buy
+37,186
New +$1.03M 0.84% 36

Other funds holding PFE

Hayek Kallen Investment Management's PFE Position: Q2 2026 in Review

Hayek Kallen Investment Management reduced its Pfizer (PFE) stake by 1.3% in Q2 2026, selling an estimated $32.1K and leaving 94,912 shares worth $2.29M. The position accounts for 0.69% of the portfolio, ranked #38.

Hayek Kallen Investment Management first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.12M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Hayek Kallen Investment Management held 94,912 shares of Pfizer worth $2.29M as of Q2 2026.
  • Hayek Kallen Investment Management sold 1,227 Pfizer shares in Q2 2026, an estimated $32.1K.
  • Pfizer made up 0.69% of Hayek Kallen Investment Management's portfolio in Q2 2026, its #38 holding.
  • Hayek Kallen Investment Management first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Hayek Kallen Investment Management's Pfizer position peaked at $6.12M in Q4 2021.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Hayek Kallen Investment Management's 13F filing for Q2 2026, filed 17 Aug 2026.